BRPI0922302B8 - extrudados com substâncias ativas aciculares, seu uso, e medicamentos - Google Patents

extrudados com substâncias ativas aciculares, seu uso, e medicamentos

Info

Publication number
BRPI0922302B8
BRPI0922302B8 BRPI0922302A BRPI0922302A BRPI0922302B8 BR PI0922302 B8 BRPI0922302 B8 BR PI0922302B8 BR PI0922302 A BRPI0922302 A BR PI0922302A BR PI0922302 A BRPI0922302 A BR PI0922302A BR PI0922302 B8 BRPI0922302 B8 BR PI0922302B8
Authority
BR
Brazil
Prior art keywords
medicines
extruded
active substances
acicular
acicular active
Prior art date
Application number
BRPI0922302A
Other languages
English (en)
Inventor
Hamann Hans-Jürgen
Kleinebudde Peter
Witzleb Rieke
Kanikanti Venkata-Rangarao
Original Assignee
Bayer Animal Health Gmbh
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41785839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922302(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh, Bayer Ip Gmbh filed Critical Bayer Animal Health Gmbh
Publication of BRPI0922302A2 publication Critical patent/BRPI0922302A2/pt
Publication of BRPI0922302B1 publication Critical patent/BRPI0922302B1/pt
Publication of BRPI0922302B8 publication Critical patent/BRPI0922302B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

extrudados com substâncias ativas aciculares. a invenção refere-se a extrudados contendo pelo menos uma substância farmaceuticamente ativa na forma da agulhas, na qual a razão do tamanho de partícula da substância farmaceuticamente ativa em forma de agulha em relação ao diâmetro do cordão é de pelo menos 1:15, e ao uso desses extrudados para a produção de medicamentos.
BRPI0922302A 2008-12-05 2009-11-24 extrudados com substâncias ativas aciculares, seu uso, e medicamentos BRPI0922302B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008060472 2008-12-05
DE102008060472.0 2008-12-05
PCT/EP2009/008341 WO2010063387A1 (de) 2008-12-05 2009-11-24 Extrudate mit nadelförmigen wirkstoffen

Publications (3)

Publication Number Publication Date
BRPI0922302A2 BRPI0922302A2 (pt) 2016-01-05
BRPI0922302B1 BRPI0922302B1 (pt) 2020-09-15
BRPI0922302B8 true BRPI0922302B8 (pt) 2021-05-25

Family

ID=41785839

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922302A BRPI0922302B8 (pt) 2008-12-05 2009-11-24 extrudados com substâncias ativas aciculares, seu uso, e medicamentos

Country Status (27)

Country Link
US (1) US20120034273A1 (pt)
EP (1) EP2373287B1 (pt)
JP (2) JP5860284B2 (pt)
KR (1) KR20110096145A (pt)
CN (1) CN102238940B (pt)
AR (1) AR075106A1 (pt)
AU (1) AU2009321822B2 (pt)
BR (1) BRPI0922302B8 (pt)
CA (1) CA2745456A1 (pt)
CL (1) CL2011001207A1 (pt)
CO (1) CO6440550A2 (pt)
CR (1) CR20110285A (pt)
DO (1) DOP2011000160A (pt)
EC (1) ECSP11011080A (pt)
ES (1) ES2685472T3 (pt)
IL (1) IL212846A0 (pt)
MX (1) MX2011005572A (pt)
NI (1) NI201100103A (pt)
NZ (1) NZ593217A (pt)
PE (1) PE20120182A1 (pt)
RU (1) RU2549450C2 (pt)
SV (1) SV2011003919A (pt)
TW (1) TWI522114B (pt)
UA (1) UA105648C2 (pt)
UY (1) UY32287A (pt)
WO (1) WO2010063387A1 (pt)
ZA (1) ZA201104145B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231017B1 (hu) * 2012-05-08 2019-11-28 LAVET Gyógyszeripari Kft. Praziquantel tartalmú ízfedett formulációk
CN111803465B (zh) * 2013-03-15 2023-05-09 阿根塔创新有限公司 可咀嚼配制物
ZA201408333B (en) * 2013-11-14 2015-12-23 Cipla Ltd Pharmaceutical compositions
CN110996920A (zh) 2017-07-26 2020-04-10 太杰先软嚼有限责任公司 用于兽医应用的无淀粉软咀嚼物
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4402752B2 (ja) * 1997-05-19 2010-01-20 大日本住友製薬株式会社 免疫増強製剤
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
ES2326794T3 (es) * 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
EP1519704A2 (en) * 2002-06-27 2005-04-06 Cilag AG Spherical pellet containing a water-soluble active ingredient
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
SI1566173T1 (sl) * 2004-02-20 2006-12-31 Mattern Udo Farmacevtska zmes za oralno aplikacijo in postopek njene priprave
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
JPWO2006090640A1 (ja) * 2005-02-23 2008-07-24 太陽化学株式会社 アミノ酸含有錠剤組成物および錠剤の製造方法
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
CN101590020B (zh) * 2008-05-30 2012-02-08 上海新菲尔生物制药工程技术有限公司 一种对氨基水杨酸钠结肠定位给药系统

Also Published As

Publication number Publication date
AU2009321822A1 (en) 2011-06-30
NZ593217A (en) 2013-05-31
UY32287A (es) 2010-06-30
CR20110285A (es) 2011-09-27
PE20120182A1 (es) 2012-02-24
JP5860284B2 (ja) 2016-02-16
ZA201104145B (en) 2012-09-26
ES2685472T3 (es) 2018-10-09
CL2011001207A1 (es) 2011-10-28
EP2373287A1 (de) 2011-10-12
BRPI0922302A2 (pt) 2016-01-05
KR20110096145A (ko) 2011-08-29
RU2549450C2 (ru) 2015-04-27
SV2011003919A (es) 2011-08-28
JP2015134812A (ja) 2015-07-27
RU2011127248A (ru) 2013-01-10
EP2373287B1 (de) 2018-05-30
MX2011005572A (es) 2011-06-16
UA105648C2 (uk) 2014-06-10
TWI522114B (zh) 2016-02-21
AU2009321822B2 (en) 2015-04-16
US20120034273A1 (en) 2012-02-09
CA2745456A1 (en) 2010-06-10
CN102238940A (zh) 2011-11-09
HK1163547A1 (en) 2012-09-14
WO2010063387A1 (de) 2010-06-10
TW201031422A (en) 2010-09-01
IL212846A0 (en) 2011-07-31
CN102238940B (zh) 2014-07-30
ECSP11011080A (es) 2011-06-30
DOP2011000160A (es) 2011-06-30
BRPI0922302B1 (pt) 2020-09-15
CO6440550A2 (es) 2012-05-15
AR075106A1 (es) 2011-03-09
NI201100103A (es) 2012-04-16
JP2012510956A (ja) 2012-05-17

Similar Documents

Publication Publication Date Title
BRPI1008023B8 (pt) Forma de dosagem sólida
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
BR112012007206A2 (pt) dispositivo de distribuição de fármacos
CL2011000891A1 (es) Uso de la cepa probiotica lactobacillus reuteri dsm17938 o una composicion nutricional que comprende una cepa bacteriana probiotica lactobacillus reuteri dsm17938 porque sirve para preparar un medicamento o una composicion nutricional util para reducir las alteraciones de sueño y/o mejorar la calidad del sueño o los patrones de sueño en humanos o animales.
CL2008001821A1 (es) Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
BR112018009812A8 (pt) fibra sintética, batedura, material isolante, fio, artigo, e, método para produção de uma fibra sintética.
BRPI0800212A (pt) sistema de envio de lente
MX2011013539A (es) Tabletas de farmaco solidas para dispositivos implantables para administrar farmacos.
AR096115A1 (es) Modificaciones cristalinas del elobixibat
BR112015021994A8 (pt) produto de papel, composição adequada para sua fabricação e processo de preparação do mesmo
BRPI0812432B8 (pt) extrusados, seu uso, e medicamento
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
BR112012023912A2 (pt) produto de artigos de confeitaria contendo componentes ativos e/ou reativos e métodos de produção do mesmo
DOP2013000224A (es) Uso de 2,3-dihidroimidazo[1,2-c] quinazolinas sustituidas.
PE20160048A1 (es) Composiciones antibioticas de ceftolozano
BR112015020000A2 (pt) fibra kraft quimicamente modificada e métodos de fabricação da mesma
CR20150455A (es) Imidazopiridazinas sustituidas
BRPI0909330A2 (pt) Método para produzir uma mistura de bacteriófagos, medicamento, mistura de fago e o uso da mesma na terapia de estafilococos resistentes a antibiótico
ES2582927T3 (es) Adhesivo para la fabricación de laminados de productos de celulosa y procedimientos de fabricación de laminados de productos de celulosa
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
CL2013002777A1 (es) Proceso para la preparacion de particulas de pigmentos autoaglutinantes, en que dicho aglutinante comprende una carboximetilcelulosa; suspension de particulas de pigmentos autoaglutinantes; y su uso.
BR112012023431A2 (pt) dispositivo de distribuição de fármacos
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
BR112015011180A2 (pt) sistema de absorção de fluido unitário para produtos absorventes e seus métodos de fabricação

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B25A Requested transfer of rights approved

Owner name: BAYER ANIMAL HEALTH GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: ELANCO ANIMAL HEALTH GMBH (DE)

B25G Requested change of headquarter approved

Owner name: ELANCO ANIMAL HEALTH GMBH (DE)